Sentiment-Signal
21,1
Stark Bearisch
Composite Score (0–100)
Insider (25%)
37
1 Insider, 298K $ Volumen
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Unternehmen & Branche
| Name | CVRx, Inc. |
|---|---|
| Ticker | CVRX |
| CIK | 0001235912 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Devices |
| SIC | 3841 · Surgical & Medical Instruments & Apparatus |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 183,4 Mio. USD |
| Beta | 1,12 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 56,651,000 | -53,306,000 | -2.04 | 104,794,000 | 39,324,000 |
| 2025-09-30 | 10-Q | 14,690,000 | -12,870,000 | -0.49 | 111,325,000 | 48,054,000 |
| 2025-06-30 | 10-Q | 13,589,000 | -14,736,000 | -0.57 | 119,564,000 | 57,934,000 |
| 2025-03-31 | 10-Q | 12,348,000 | -13,766,000 | -0.53 | 129,589,000 | 71,055,000 |
| 2024-12-31 | 10-K | 51,292,000 | -59,965,000 | -2.65 | 133,414,000 | 71,055,000 |
| 2024-09-30 | 10-Q | 13,373,000 | -13,099,000 | -0.57 | 127,673,000 | 65,183,000 |
| 2024-06-30 | 10-Q | 11,807,000 | -14,029,000 | -0.65 | 95,981,000 | 55,248,000 |
| 2024-03-31 | 10-Q | 10,770,000 | -22,186,000 | -1.04 | 106,171,000 | 66,261,000 |
| 2023-12-31 | 10-K | 39,295,000 | -41,199,000 | -1.99 | 115,229,000 | 75,947,000 |
| 2023-09-30 | 10-Q | 10,511,000 | -9,011,000 | -0.43 | 106,404,000 | 82,827,000 |
| 2023-06-30 | 10-Q | 9,500,000 | -11,651,000 | -0.56 | 114,973,000 | 89,964,000 |
| 2023-03-31 | 10-Q | 7,979,000 | -11,374,000 | -0.55 | 122,691,000 | 99,642,000 |
| 2022-12-31 | 10-K | 22,469,000 | -41,428,000 | -2.02 | 124,937,000 | 109,180,000 |
| 2022-09-30 | 10-Q | 6,186,000 | -9,830,000 | -0.48 | 126,576,000 | 118,244,000 |
| 2022-06-30 | 10-Q | 5,031,000 | -11,071,000 | -0.54 | 134,037,000 | 127,146,000 |
| 2022-03-31 | 10-Q | 4,076,000 | -9,991,000 | -0.49 | 144,405,000 | 136,803,000 |
| 2021-12-31 | 10-K | 13,036,000 | -43,078,000 | -4.16 | 152,548,000 | 145,959,000 |
| 2021-09-30 | 10-Q | 3,395,000 | -6,133,000 | -0.30 | 181,707,000 | 155,763,000 |
| 2021-06-30 | 10-Q | 3,123,000 | -17,748,000 | -48.48 | 55,062,000 | -318,931,000 |
| 2021-03-31 | 10-Q | 2,860,000 | -8,627,000 | -23.92 | -301,806,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-02 | OASHEIM JARED | Officer, CHIEF FINANCIAL OFFICER | Open Market Sale | -1,744 | 7.90 | -13,781.44 | -11,3% | |
| 2026-03-02 | Adamson Philip B. | Officer, Chief Medical Officer | Open Market Sale | -1,262 | 7.90 | -9,973.21 | -8,1% | |
| 2026-03-02 | John Robert Allen | Officer, Chief Revenue Officer | Open Market Sale | -3,964 | 7.90 | -31,325.51 | -25,6% | |
| 2026-03-02 | VERRASTRO PAUL | Officer, CHIEF MKTG & STRAT OFFICER | Open Market Sale | -1,284 | 7.90 | -10,146.30 | -8,3% | |
| 2026-03-02 | Hykes Kevin | Director, Officer, PRES & CEO | Open Market Sale | -7,763 | 7.90 | -61,348.66 | -50,1% | |
| 2026-02-20 | Jain Mudit K. | Director | Open Market Purchase | 46,800 | 6.36 | 297,591.84 | +243,2% | |
| 2026-02-18 | Jain Mudit K. | Director | Open Market Purchase | 600 | 4.64 | 2,785.02 | +2,3% | |
| 2025-11-26 | JOHNSON & JOHNSON | 10% Owner | Open Market Sale | -6,337 | 10.03 | -63,560.11 | -51,9% | |
| 2025-11-26 | JOHNSON & JOHNSON | 10% Owner | Open Market Sale | -6,337 | 10.03 | -63,560.11 | -51,9% | |
| 2025-11-25 | JOHNSON & JOHNSON | 10% Owner | Open Market Sale | -16,000 | 10.03 | -160,480.00 | -131,1% | |
| 2025-11-24 | JOHNSON & JOHNSON | 10% Owner | Open Market Sale | -2,200 | 10.06 | -22,132.00 | -18,1% | |
| 2025-11-21 | JOHNSON & JOHNSON | 10% Owner | Open Market Sale | -500 | 10.00 | -5,000.00 | -4,1% | |
| 2025-11-12 | JOHNSON & JOHNSON | 10% Owner | Open Market Sale | -1,000 | 10.00 | -10,000.00 | -8,2% | |
| 2025-11-07 | JOHNSON & JOHNSON | 10% Owner | Open Market Sale | -200 | 10.00 | -2,000.00 | -1,6% | |
| 2025-11-06 | JOHNSON & JOHNSON | 10% Owner | Open Market Sale | -52,332 | 10.21 | -534,309.72 | -436,6% | |
| 2025-05-15 | Nielsen Kirk G. | Director | Open Market Purchase | 10,966 | 5.45 | 59,795.40 | +48,9% | |
| 2025-05-14 | Nielsen Kirk G. | Director | Open Market Purchase | 61,200 | 5.23 | 320,363.64 | +261,8% | |
| 2025-05-13 | Nielsen Kirk G. | Director | Open Market Purchase | 101,413 | 5.29 | 536,312.51 | +438,3% | |
| 2025-05-12 | Nielsen Kirk G. | Director | Open Market Purchase | 25,200 | 4.79 | 120,670.20 | +98,6% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.